Recipharm

Recipharm is a global Contract Development and Manufacturing Organization (CDMO) that provides comprehensive pharmaceutical development and manufacturing services. The company specializes in offering end-to-end solutions, from early-stage drug development to commercial production, encompassing a broad range of dosage forms including oral solids, sterile fill-finish, and complex formulations. Its capabilities span active pharmaceutical ingredient (API) manufacturing, drug product manufacturing, and development services, leveraging scientific expertise and operational excellence to support the pharmaceutical industry.

The company was established in March 1995 when Thomas Eldered and Lars Backsell executed a management buyout of a Pharmacia solid dose tablet manufacturing facility in Årsta, Stockholm. This strategic move, driven by their deep understanding of pharmaceutical production and market needs, formed the foundation of Recip, which later evolved into Recipharm. Eldered, serving as CEO, and Backsell, a key member of the management team, aimed to build a robust CDMO focused on quality and client partnerships.

Recipharm serves a diverse global clientele of pharmaceutical and biotech companies, assisting them in bringing essential medicines to market. The company’s vision centers on being a trusted partner for its clients, offering flexible and integrated solutions across the entire drug lifecycle. It strives to continuously enhance its scientific know-how and operational capabilities, positioning itself as a leading global CDMO committed to advancing pharmaceutical innovation and patient access to medicines.